Jonathan D. Cheng
California State University, Northridge(US)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Head and Neck Cancer Studies, Peptidase Inhibition and Analysis, Lung Cancer Treatments and Mutations, Cancer Genomics and Diagnostics
Most-Cited Works
- → IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade(2017)3,762 cited
- → Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study(2019)3,087 cited
- → Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy(2018)2,281 cited
- → Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial(2016)1,717 cited
- → Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer(2018)1,688 cited
- → Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study(2018)1,654 cited
- → Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study(2016)1,455 cited
- → Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort(2016)850 cited
- → Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study(2017)643 cited
- → PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer(2017)593 cited